# US 2013/0253028 A1 · Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0253028 A1
- Document ID: US20130253028A1
- Status: Published application
- Kind: A1
- Application number: 13/898,254
- Filed: 2013-05-20
- Published: 2013-09-26
- Earliest claimed: 2010-07-01
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: WILLIAM R. CARLING; JOSE L. MARTOS; DAVID F. WOODWARD; JENNY W. WANG; JUSSI J. KANGASMETSA
- Web page: https://patentgrep.com/patent/US20130253028A1

## CPC

- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A61K 31/415: 1,2-Diazoles
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy}halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid. The compound may be represented by the following formula Wherein R1, R2, R3, R4, R5, R6, X, W, X and Y are as defined in the specification. The compounds may be administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions.

## Claims

### Claim 1

A compound, that is a 1-[(2-{[(alkyl or aryl)methyl]oxy} halo or haloalkyl substituted-phenyl)alkyl]-5-hydrocarbyl or substituted hydrocarbyl-1H-pyrazole carboxylic acid or alkylenylcarboxylic acid or a hydrocarbyl or substituted hydrocarbyl sulfonamide of said carboxylic acid or said alkylenylcarboxylic acid, provided however said compound is not a 3-carboxylic acid, a sulfonamide thereof, or a 3-methylenylcarboxylic acid.

### Claim 2 (depends on 1)

A compound according to claim 1, wherein said 5-hydrocarbyl is 5-methyl.

### Claim 3 (depends on 2)

A compound according to claim 2, wherein said halo or haloalkyl substituted-phenylalkyl is halo or haloalkyl substituted-phenyl)methyl.

### Claim 4 (depends on 3)

A compound according to claim 3, that is a 1-[(2-{[(alkyl)methyl]oxy} halo or haloalkyl-substituted phenyl)methyl]-5-methyl-1H-pyrazole-3-ethylenylcarboxylic acid, wherein said halo is selected from the group consisting of fluoro, chloro and bromo.

### Claim 5 (depends on 3)

A compound according to claim 3, that is a 1-[(2-{[(aryl)methyl]oxy} halo or haloalkyl-substituted phenyl)methyl]-5-methyl-1H-pyrazole-3-carboxylic acid fluoro-substituted alkylsulfonamide or alkylenylcarboxylic acid fluoro-substituted alkylsulfonamide, wherein said halo is selected from the group consisting of fluoro, chloro and bromo.

### Claim 6 (depends on 4)

The compound of claim 4, wherein said halo or haloalkyl-substituted phenyl is selected from the group consisting of trifluoromethylphenyl, chlorophenyl and bromophenyl.

### Claim 7 (depends on 3)

The compound of claim 3, wherein said halo or haloalkyl-substituted phenyl is selected from the group consisting of trifluoromethylphenyl, chlorophenyl and bromophenyl.

### Claim 8 (depends on 1)

The compound of claim 1, wherein said compound is a trifluoromethylsulfonamide and said aryl is chlorophenyl.

### Claim 9 (depends on 6)

The compound of claim 6, wherein said alkyl is 3-pentyl.

### Claim 10 (depends on 6)

The compound of claim 6, wherein said alkyl is cyclopentyl.

### Claim 11 (depends on 6)

The compound of claim 6, wherein W is cyclopentyl.

### Claim 12

A method for decreasing the secretion of cytokines from a macrophage comprising administering a compound having the following formula
Wherein R1 is selected from the group consisting of OR7, N(R7)2, and N(R2)SO2R7 wherein R7 is selected from the group consisting of H, alkyl and aryl, wherein said alkyl and aryl may be substituted with fluoro;
R2 is selected from the group consisting of H and alkyl;
R3 is selected from the group consisting of H and alkyl; wherein R2 and R3, individually or together, can form a cycloalkyl ring;
X is (CH2)n wherein n is 0 or an integer of from 1 to 3, provided however that when n is 0 or 1, R1 is not OR7. or NR2;
R4 is selected from the group consisting of H, alkyl and fluoroalkyl;
R5 is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy or aryloxy;
R6 is selected from the group consisting of H, hydroxy, alkyl, aryl, alkoxy, aryloxy, halogen, nitro, amino, cyano and hydroxy, halogen, nitro, amino and cyano-substituted alkyl, aryl, alkoxy and aryloxy;
Z is (CH2)m wherein m is 0 or an integer of from 1 to 3;
Y is selected from the group consisting of O, S, SO, SO2 and (CH2)p, wherein p is 0 or an integer of from 1 to 3; and
W is selected from the group consisting of alkyl and aryl.

### Claim 13 (depends on 12)

The method of claim 12, wherein said compound is administered to treat DP1, FP, EP1, TP and/or EP4 receptor mediated diseases or conditions.

### Claim 14 (depends on 12)

A method according to claim 12, wherein said cytokine is TNFα and said compound is administered for treating diseases resulting from the stimulation of the production of proinflammatory cytokines/chemokines, collagenases, metalloproteinases, and other inflammatory mediators; activation of endothelial cells and neutrophils; promotion T- and B-cell growth, as well as stimulation of bone resorption, the production of local and systemic proinflammatory cytokines/chemokines and serum MMP-3, nitric oxide synthase activity, VEGF release, and angiogenesis in inflamed joints.

### Claim 15 (depends on 12)

A method according to claim 12, wherein said macrophage is a human macrophage.
